Event-Driven Stocks

Inozyme Pharma, Inc.

INZY

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 1 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY24FY23FY22FY21FY20FY19
Revenue——————
Operating income−$104.0M−$75.6M−$68.7M−$56.6M−$57.0M−$20.8M
Net income−$102.0M−$71.2M−$67.1M−$56.6M−$56.4M−$19.7M
Total assets$123.2M$200.8M$139.2M$123.5M$169.4M$47.9M
Total liabilities$65.4M$60.4M$20.8M$14.3M$11.3M$3.2M
Equity$57.8M$140.5M$118.4M$109.3M$158.1M−$33.2M
EPS (diluted)$-1.62$-1.37$-1.78$-2.40——
Shares out.64.2M43.7M23.7M23.5M23.4M1.2M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2024
Operating margin
—
Net margin
—
Return on equity
−176.4%
Return on assets
−82.8%
Return on capital (ROCE)
−116.5%
Liabilities / assets
53.1%
Debt / equity
1.13×
Book value / share
$0.90
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2024
Altman Z″ (distress)
-10.39distress
Accruals / assets
−8.2%clean
Piotroski F-Score
1/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
52
/ 100
Profitability 0Growth n/aCatalyst 67Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 1 warning● 1 good
  • Altman Z″ in the distress zone
  • Negative operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Jun 30, 20251.5M1.2-55.0%
Jun 13, 20253.4M3.8-8.0%
May 30, 20253.7M1.0-4.1%
May 15, 20253.8M1.7-3.7%
Apr 30, 20254.0M9.1-9.9%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)